PURPOSE: To compare retrospectively the outcomes and complications of transcatheter arterial chemoembolization with drug-eluting embolic agents combined with radiofrequency (RF) ablation or microwave (MW) ablation in treatment of @entity157 ( @entity157 ). MATERIALS AND METHODS: From 2003-2011, 89 @entity1 with @entity157 received a combination therapy-transcatheter arterial chemoembolization plus RF ablation in 38 @entity1 and transcatheter arterial chemoembolization plus MW ablation in 51 @entity1 . @entity5 response, @entity5 progression-free survival (PFS), overall PFS, @entity1349 ( @entity1349 ), and complications were compared. Overall PFS and @entity1349 were compared between the two treatment groups in multivariate analysis controlling for @entity1 -Pugh class, Barcelona Clinic Liver Classification stage, and index @entity5 size. RESULTS: Complete local @entity5 response was achieved in 37 (80.4%) of the @entity5 treated with transcatheter arterial chemoembolization plus RF ablation and 49 (76.6%) of the @entity5 treated with transcatheter arterial chemoembolization plus MW ablation (P = .67). The median @entity5 PFS and overall PFS were 20.8 months and 9.3 months (P = .72) for transarterial chemoembolization plus RF ablation and 21.8 months and 9.2 months for transarterial chemoembolization plus MW ablation (P = .32). The median @entity1349 of the transcatheter arterial chemoembolization plus RF ablation group was 23.3 months, and the median @entity1349 of the transcatheter arterial chemoembolization plus MW ablation group was 42.6 months, with no significant difference in the survival experience between the two groups (log-rank test, P = .10). In the multivariate analysis, Barcelona Clinic Liver Classification stage was the only factor associated with overall PFS and @entity1349 . One @entity1 in the transcatheter arterial chemoembolization plus RF ablation cohort (3%) and two @entity1 in the transcatheter arterial chemoembolization plus MW ablation cohort (4%) required prolonged hospitalization (< 48 h) for @entity158 management after the procedure (P = 1.00). CONCLUSIONS: Based on similar safety and efficacy outcomes, both combination therapies, transcatheter arterial chemoembolization plus RF ablation and transcatheter arterial chemoembolization plus MW ablation, are effective treatments for @entity157 .

Comparison of Combination Therapies in the Management of XXXX : Transarterial Chemoembolization with Radiofrequency Ablation versus Microwave Ablation.

@entity1 :: ('9606', 'Species') :: ['Child', 'patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Local tumor', 'tumors'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity157 :: (MESH:D006528,Disease) :: ['Hepatocellular Carcinoma']
